An Open Label, Multicenter, Non-Comparative, Phase IV Study of Panitumumab to Characterize Its Safety, Tolerability and Activity in Indian Subjects With Previously Treated Wild-Type RAS (KRAS and NRAS), Metastatic Colorectal Cancer

Trial Profile

An Open Label, Multicenter, Non-Comparative, Phase IV Study of Panitumumab to Characterize Its Safety, Tolerability and Activity in Indian Subjects With Previously Treated Wild-Type RAS (KRAS and NRAS), Metastatic Colorectal Cancer

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs Panitumumab (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 05 Apr 2018 Planned primary completion date changed from 31 Mar 2018 to 30 Jun 2019.
    • 08 Feb 2018 Planned End Date changed from 31 Mar 2018 to 30 Jun 2019.
    • 05 Dec 2017 Planned primary completion date changed from 1 Nov 2017 to 31 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top